Novavax
United States
829 articles with Novavax
-
It was yet another busy week for clinical trial news, with a range of studies for COVID-19, various cancers, fungal infections and other indications.
-
Novavax Announces Initiation of COVID-19 Vaccine Booster Study in Adolescents in Phase 3 PREVENT-19 Trial
4/22/2022
Novavax, Inc. has initiated administration of the first booster doses of NVX-CoV2373.
-
Although treating patients is the top priority of the biopharma industry, there’s no doubt that money is the driver. This is a broad look at the current state of biopharma bucks.
-
The FDA noted that the EUA application for Novavax's COVID-19 shot may take a while to be resolved, citing an "incredibly complex review process."
-
Initial Results from Novavax' COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine
4/20/2022
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced initial results from the Phase 1/2 clinical trial of its COVID-Influenza Combination Vaccine (CIC).
-
Novavax Announces Approval of Nuvaxovid™ COVID-19 Vaccine for Primary and Booster Immunization in Japan
4/19/2022
Nuvaxovid is the first protein-based COVID-19 vaccine approved for use in adults aged 18 and older in Japan Approval is first in the world for NVX-CoV2373 that includes both primary and booster vaccination.
-
Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology & Infectious Diseases
4/18/2022
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, will provide a first look at data from its COVID-19 influenza combination vaccine and seasonal influenza vaccine trials, at the World Vaccine Congress (WVC) in Washington, DC, April 18 - 21, 2022.
-
Swissmedic Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine
4/13/2022
Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced that Swissmedic, the Swiss Agency for Therapeutic Products, has granted Novavax conditional marketing authorization for Nuvaxovid™ COVID-19 Vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.
-
Novavax and Serum Institute of India Receive Emergency Use Authorization for Novavax' COVID-19 Vaccine in Thailand
4/8/2022
Novavax, Inc. and Serum Institute of India Pvt. Ltd. announced that the Thailand Food and Drug Administration has granted emergency use authorization for Novavax' protein-based vaccine for active immunization to prevent coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 in individuals 18 years of age and older.
-
Novavax Submits Request to Expand Conditional Marketing Authorization of COVID-19 Vaccine in the European Union to Adolescents (Ages 12-17)
3/31/2022
Novavax, Inc. announced submission of its request to expand the conditional marketing authorization of Nuvaxovid™ COVID-19 Vaccine in the European Union to adolescents aged 12 through 17 years.
-
Novavax Announces Participation in Two Booster Studies Using its COVID-19 Vaccine
3/25/2022
Novavax, Inc. (Nasdaq: NVAX), today announced that NVX-CoV2373, its protein-based COVID-19 vaccine, is included in two trials now underway to evaluate its vaccine's safety, immunogenicity, and reactogenicity as a booster amidst the ongoing COVID-19 pandemic.
-
Novavax announced today that its protein-based Covid-19 vaccine, NVX-CoV2373, is included in two new clinical trials that will evaluate the vaccine as a potential Covid booster.
-
Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax' COVID-19 Vaccine in Adolescents ≥12 to & 18 in India
3/22/2022
Novavax, Inc. (Nasdaq: NVAX), and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine manufacturer by volume, announced that the Drugs Controller General of India (DCGI) has granted emergency use authorization (EUA) for Novavax' protein-based COVID-19 vaccine for adolescents aged ≥12 to <18 years in India.
-
Many countries around the world that appeared to have kicked COVID-19, are reporting surges, largely the result of the so-called “stealth” Omicron variant, BA.2, and more COVID news.
-
Novavax to Participate in Cowen's 42nd Annual Health Care Conference
3/2/2022
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in Cowen's 42nd Annual Healthcare Conference.
-
Novavax Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
2/28/2022
Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced its financial results and operational highlights for the fourth quarter and twelve months ended December 31, 2021.
-
Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial
2/28/2022
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today shared extended analysis from its pivotal Phase 3 clinical trial conducted in the United Kingdom (UK), showing that a high level of efficacy for its protein-based COVID-19 vaccine, NVX-CoV2373, was maintained over a 6-month period of surveillance.
-
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights on February 28, 2022
2/21/2022
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its fourth quarter and full year 2021 financial results and operational highlights on Monday, February 28, 2022, following the close of U.S. financial markets.
-
It was noted early in the COVID-19 pandemic that the disease was peculiar — not only was it a respiratory disease, but it created hyper-immune responses.
-
Health Canada Authorizes Novavax COVID-19 Vaccine
2/17/2022
Novavax, Inc. announced that Health Canada has granted authorization for Nuvaxovid™ COVID-19 Vaccine for active immunization to prevent coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 in individuals 18 years of age and older.